Streetbeat News

Products Services

CDTX

Cidara Therapeutics anticipates incurring approximately $1.2 million in charges for severance payments and employee benefits, mainly in Q4 2024. The company also plans to start a Phase 2b clinical trial for CD388, aimed at preventing influenza, in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:23 pm

BA

UAL

United Airlines executives express growing confidence in Boeing, noting stabilized 737 delivery rates and positive leadership under Boeing's new CEO. However, concerns remain about ramp rates for the 787 and persistent engine supply constraints.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:22 pm

LHX

L3Harris Technologies has secured a 5-year contract valued at up to $587.4 million to provide custom tactical jamming pods for the US Navy. This contract aims to enhance the Navy's aerial electronic attack capabilities.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:16 pm

OXY

Occidental's subsidiary, 1PointFive, has been awarded up to $500 million by the U.S. Department of Energy to develop a Direct Air Capture Hub in South Texas, with potential funding increasing to $650 million for regional expansion.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:14 pm

WKHS

Workhorse Group Inc. is participating as a Presidential Exhibitor at the 2024 FedEx Forward Service Provider Summit, showcasing its W56 electric vehicle. The event highlights transportation innovation and the future of logistics.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:13 pm

QGEN

QIAGEN has expanded its partnership with Bio-Manguinhos/Fiocruz to enhance Brazil's public health capabilities. The collaboration now includes advanced PCR-based molecular screening for malaria, HIV, HBV, and HCV, and supports dengue surveillance with unique molecular kits.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:11 pm

NBIX

Neurocrine Biosciences announced that their Phase 2 study for Luvadaxistat did not meet its primary endpoint for treating cognitive impairment in schizophrenia. The company will now focus on Phase 3 development of other drugs for schizophrenia and major depressive disorder.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:11 pm

IMRX

Immuneering shares rise following positive initial response data from a Phase 2a clinical trial involving IMM-1-104 for pancreatic cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:10 pm

IMRX

Immuneering has announced initial Phase 2a data for its treatment IMM-1-104 combined with modified Gemcitabine/Nab-Paclitaxel. The results from the first five patients show a 40% overall response rate (ORR) and an 80% disease control rate.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:09 pm

CDTX

Cidara Therapeutics is reducing its workforce by 30% to focus on the clinical development of CD388, a drug candidate for influenza A and B. This strategic move aims to reduce capital needs and prioritize upcoming trials. The company is also pursuing business development for its oncology programs.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:09 pm